Shenandoah, Iowa (PRWEB) July 15, 2014
LLOYD, Inc. has announced the appointment of Dr. Erik R. Martinez as CEO. Dr. Martinez assumed responsibilities on 7/7/2014 and will succeed interim CEO Dr. W. Eugene Lloyd, who will continue as Chairman of the Board of Directors of LLOYD, Inc.
Dr. Lloyd states: “The Board or Directors of LLOYD, Inc. and all employees are delighted that Dr. Martinez has joined the company in this very important leadership position. His vast industry experience will undoubtedly lead the company to achieve significant advances in marketing and corporate operations.”
Dr. Martinez states “I am very excited to join LLOYD, Inc. as CEO at this pivotal time when the company is ready to make a great come back with its flagship product Thyro-Tabs® Canine and Human Levothyroxine Sodium Tablets, USP. ”
Dr. Martinez is a seasoned Global Animal Health Pharmaceutical Executive with an outstanding international track record with Virbac including General Manager (Mexico) Regional Director (Latin America), Pacific Area Director (Australia), and President and CEO (North America). His prior experiences with Boehringer Ingelheim Vetmedica, and Elanco round out a wealth of industry expertise. Dr. Martinez is a veterinarian, has an MBA, and speaks four languages.
LLOYD, Inc. is a research-based company with several new products in development. The company is positioned to become a world leader in both the canine and human levothyroxine sodium tablet markets. In total, LLOYD provides more than two hundred products/package sizes to some forty thousand veterinarians and physicians in the U.S. and thousands more around the world. LLOYD products aid in the treatment of disease and nutritional deficiencies. The company works in partnership with more than sixty distributors and private label customers in the U.S. and worldwide.